Patents Assigned to Nektar Therapeutics
  • Identifying dry nebulizer elements
    Patent number: 9272101
    Abstract: Various arrangements for determining whether a liquid is in contact with a nebulizer element are disclosed. A nebulizer element may be energized with an electrical signal at a measurement frequency. An impedance of the nebulizer element may be measured, thereby obtaining a measured impedance value. The impedance value may be compared to a stored impedance value. Based on the comparison, it may be determined whether the liquid contacts the nebulizer element.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: March 1, 2016
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Benjamin Morris Gordon, Steven David Gardner, Thomas Edward Parker
  • Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
    Patent number: 9274122
    Abstract: The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: March 1, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH, NEKTAR THERAPEUTICS
    Inventors: Katalin Varadi, Gerald Schrenk, Hanspeter Rottensteiner, Peter Turecek, Alfred Weber, Heinz Anderle, Sean M. Culbertson, Zhihao Fang, Harold Zappe, Ping Zhang, Mary J. Bossard
  • Oligomer-containing substituted aromatic triazine compounds
    Patent number: 9266845
    Abstract: The invention relates to (among other things) methods for treatment comprising administering oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: February 23, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Aerosolization device
    Patent number: 9242054
    Abstract: An aerosol transfer device for medical aerosol generators includes a body, fluidically coupled to a nebulizer and to a patient interface. An ambient air intake is formed into a lower body. The body is shaped and configured to optimize mixing of ambient air from the ambient air intake and the aerosol generated by the nebulizer, resulting in the formation of an aerosol plume having optimum characteristics for delivery of the aerosol to the patient's pulmonary system, such as the central or deep lung regions. The shape and dimensions of the body are further designed to minimize aerosol deposition, thus improving delivery efficiency.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: January 26, 2016
    Assignee: Nektar Therapeutics
    Inventors: James B. Fink, Nani P. Kadrichu
  • Oligomer-opioid agonist conjugates
    Patent number: 9233168
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-opioid agonist conjugates
    Patent number: 9233167
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-bis-chromonyl compound conjugates
    Patent number: 9233169
    Abstract: The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Oligomer-aryloxy-substituted propanamine conjugates
    Patent number: 9233165
    Abstract: The invention relates to (among other things) oligomer-aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: January 12, 2016
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte
  • Oligomer-nitroimidazole anti-infective conjugates
    Patent number: 9233932
    Abstract: The invention provides (among other things) small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: January 12, 2016
    Assignee: Nektar Therapeutics
    Inventors: Zhongxu Ren, Jennifer Riggs-Sauthier, Michael D. Bentley
  • Salt form of a multi-arm polymer-drug conjugate
    Patent number: 9226969
    Abstract: Among other aspects, provided herein is a hydrohalide salt of a multi-arm water-soluble polyethylene glycol-drug conjugate, along with related methods of making and using the same. The hydrohalide salt is stably formed, and appears to be more resistant to hydrolytic degradation than the corresponding free base form of the conjugate.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: January 5, 2016
    Assignee: Nektar Therapeutics
    Inventors: Anthony O. Chong, Seoju Lee, Bhalchandra V. Joshi, Brian Bray, Shaoyong Nie, Patrick L. Spence, Antoni Kozlowski, Samuel P. McManus, Sachin Tipnis, David Swallow, John R. Handley, Anthony G. Schaefer
  • N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
    Patent number: 9226971
    Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: January 5, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
    Patent number: 9228053
    Abstract: Provided herein are polymeric ?-hydroxy aldehyde or ?-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the ?-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: January 5, 2016
    Assignee: Nektar Therapeutics
    Inventors: Sean M. Culbertson, Xiaoming Shen, Antoni Kozlowski, Samuel P. McManus
  • Oligomer modified diaromatic substituted compounds
    Patent number: 9226970
    Abstract: Disclosed are compounds comprising diaromatic substituted compound residues, namely the anti-viral (anti-HIV) drug delavirdine, covalently attached via a linkage to water-soluble, non-peptidic oligomers, specifically to poly(ethylene glycol) (PEG) oligomers. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over non-oligomer modified diaromatic substituted compounds.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: January 5, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Non-ring hydroxy substituted taxanes and methods for synthesizing the same
    Patent number: 9199954
    Abstract: The invention relates to (among other things) non-ring hydroxy substituted taxanes and methods for synthesizing the same. The invention further relates to conjugating the non-ring hydroxyl substituted taxanes to a water-soluble, non-peptidic polymer.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 1, 2015
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus
  • VIBRATION SYSTEMS AND METHODS
    Publication number: 20150340590
    Abstract: In one arrangement, a vibration system includes a vibratable plate, a support member surrounding the vibratable plate, and a vibration-inducing member surrounding the support member. The vibration-inducing member is configured to radially expand and contract against the support member so as to produce axial vibration of the vibratable plate. In another arrangement, the vibratable plate has an outer circumference; a tubular member is concentrically disposed about the outer circumference of the plate, and an annular vibration-inducing member is concentrically disposed about the outer circumference of the tubular member. The vibration-inducing member is preferably a piezoelectric ring that is radially expandable and contractable against the wall of the tubular member to cause the plate to vibrate in the axial direction.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: Nektar Therapeutics
    Inventor: Yehuda Ivri
  • Oligomer-amino acid conjugates
    Patent number: 9192681
    Abstract: The invention relates to (among other things) oligomer-amino acid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated amino acid compounds.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: November 24, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Compositions Comprising a Polymeric Reagent and a Pharmacologically Active Agent
    Publication number: 20150328331
    Abstract: Pharmaceutical compositions of conjugates are provided. The conjugates can be prepared by (among other ways) conjugating a pharmacologically active agent with a polymeric reagent that has a particular arrangement of atoms. Related methods, preparations, and so forth are also provided.
    Type: Application
    Filed: May 22, 2015
    Publication date: November 19, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
  • Branched polymers
    Patent number: 9187569
    Abstract: The present invention is directed to branched reactive water-soluble polymers comprising at least two polymer arms, such as poly(ethylene glycol), attached to a central aliphatic hydrocarbon core molecule through heteroatom linkages. The branched polymers bear at least one functional group for reacting with a biologically active agent to form a biologically active conjugate. The functional group of the branched polymer can be directly attached to the aliphatic hydrocarbon core or via an intervening linkage, such as a heteroatom, -alkylene-, —O-alkylene-O—, -alkylene-O-alkylene-, -aryl-O—, —O-aryl-, (—O-alkylene-)m, or (-alkylene-O—)m linkage, wherein m is 1-10.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: November 17, 2015
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Xuan Zhao, Xiaoming Shen, William D. Battle, III
  • Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom
    Patent number: 9173947
    Abstract: The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: November 3, 2015
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski
  • Carbohydrate-based drug delivery polymers and conjugates thereof
    Patent number: 9173951
    Abstract: Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: November 3, 2015
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Xiaoming Shen